Date

Kenorland Minerals Identifies Significant Gold-in-Till Geochemical Anomaly at the 100% Owned South Uchi Project in the Red Lake District of Northwestern Ontario

Retrieved on: 
Wednesday, February 28, 2024

The survey focused on a number of different mineral system targets (Au, Ni-Cu, Li) across the 83,385-hectare property.

Key Points: 
  • The survey focused on a number of different mineral system targets (Au, Ni-Cu, Li) across the 83,385-hectare property.
  • Results from the fine fraction till sampling identified the Papaonga target, defined by a large-scale, coherent gold-in-till anomaly and a strong multi-element signature of Au-Ag-Te-W±As-Sb.
  • The Papaonga gold-in-till anomaly covers approximately five kilometers striking east-west and eight kilometers northeast-southwest following the prominent ice flow direction.
  • There has been very limited historical exploration, and no historical drilling has occurred within the geochemical source target area.

Freddie Mac Prices Approximately $618 Million Securitization of Re-Performing Loans

Retrieved on: 
Tuesday, March 5, 2024

Freddie Mac Seasoned Credit Risk Transfer Trust, Series 2024-1 includes approximately $585 million in guaranteed senior certificates and $32 million in non-guaranteed mezzanine and subordinate certificates.

Key Points: 
  • Freddie Mac Seasoned Credit Risk Transfer Trust, Series 2024-1 includes approximately $585 million in guaranteed senior certificates and $32 million in non-guaranteed mezzanine and subordinate certificates.
  • To date, Freddie Mac has sold over $10.2 billion of Non-Performing Loans (NPLs) and securitized approximately $78 billion of RPLs consisting of over $30 billion of fully guaranteed PCs, $35 billion of SCRT senior/sub securities, and $12 billion of Seasoned Loans Structured Transaction (SLST) securities.
  • Additional information about the company's seasoned loan offerings can be found at: http://www.freddiemac.com/seasonedloanofferings/
    This announcement is not an offer to sell any Freddie Mac securities.
  • Freddie Mac undertakes no obligation, and disclaims any duty, to update any of the information in those documents.

Bitcoin Well Announces Brokered Financing Led by Haywood Securities

Retrieved on: 
Monday, March 4, 2024

EDMONTON, Alberta, March 04, 2024 (GLOBE NEWSWIRE) --  Bitcoin Well Inc. (“Bitcoin Well” or the “Company”) (TSXV: BTCW; OTCQB: BCNWF), the non-custodial bitcoin business on a mission to enable independence, is pleased to announce that it has entered into an agreement with Haywood Securities Inc. (“Haywood”) dated February 29, 2024 to act as sole agent and sole bookrunner to assist the Company in selling on a commercially reasonable efforts private placement basis, units of the Company (each, a “Unit”) at a price of C$0.175 per Unit (the “Issue Price”) for gross proceeds of a minimum of C$1,250,000 (from the sale of a minimum 7,142,857 Units) and a maximum of C$2,100,000 (from the sale of a maximum of 12,000,000 Units) (the “Offering”).

Key Points: 
  • The Company intends to use the net proceeds of the Offering for sales and marketing, working capital and general corporate purposes.
  • The securities offered under the Listed Issuer Financing Exemption will not be subject to a statutory hold period in accordance with applicable Canadian securities laws.
  • All securities not issued pursuant to the Listed Issuer Financing Exemption will be subject to a hold period in accordance with applicable Canadian securities law, expiring four months and one day following the Closing Date.
  • The Company expects to close the Offering on or about March 22, 2024, or such other date as the Company and Haywood may agree.

Verizon announces accepted amounts and pricing terms of its tender offers for five series of its debt securities

Retrieved on: 
Thursday, February 29, 2024

(2) Payable per each €1,000 principal amount of each specified series of Notes validly tendered at or prior to the Early Participation Date and accepted for purchase.

Key Points: 
  • (2) Payable per each €1,000 principal amount of each specified series of Notes validly tendered at or prior to the Early Participation Date and accepted for purchase.
  • Kroll Issuer Services Limited is acting as the Tender Agent and the Information Agent for the Offers.
  • You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers.
  • In this communication Verizon has made forward-looking statements, including regarding the conduct and completion of the Offers.

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

Herbal medicinal product: Fumariae herbaArray, F: Assessment finalised

Retrieved on: 
Tuesday, March 12, 2024

Overview

Key Points: 
  • Overview
    The European Medicines Agency is currently developing this information.
  • Key facts
    - Latin name
    - Fumariae herba
    - English common name
    - Fumitory
    - Botanical name
    Fumaria officinalis L.
    - Therapeutic area
    - Gastrointestinal disorders
    - Status
    - F: Assessment finalised
    - Date added to the inventory
    - Date added to priority list
    - Outcome of European assessment
    - European Union herbal monograph

Herbal medicinal product: Foeniculi dulcis fructusArray, F: Assessment finalised

Retrieved on: 
Tuesday, March 12, 2024

Herbal medicinal product: Foeniculi dulcis fructusArray, F: Assessment finalised

Key Points: 


Herbal medicinal product: Foeniculi dulcis fructusArray, F: Assessment finalised

Herbal medicinal product: Foeniculi amari fructusArray, F: Assessment finalised

Retrieved on: 
Tuesday, March 12, 2024

Overview

Key Points: 
  • Overview
    The European Medicines Agency is currently developing this information.
  • Key facts
    - Latin name
    - Foeniculi amari fructus
    - English common name
    - Bitter Fennel
    - Botanical name
    Foeniculum vulgare Miller subsp.
  • vulgare var.
  • vulgare
    - Therapeutic area
    - Urinary tract and genital disorders
    - Cough and cold
    - Status
    - F: Assessment finalised
    - Date added to the inventory
    - Date added to priority list
    - Outcome of European assessment
    - European Union herbal monograph
    - European Union list entry
    - Additional information
    - Date of adoption of Community list entry by HMPC: 07/09/07
    - Transmission to the European Commission: 21/12/07
    - Commission Decisions on Community list entries

Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024

Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data